Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes

Details for Australian Patent Application No. 2005229416 (hide)

Owner Novartis AG

Inventors Tuli, Davinder; Bebernitz, Gregory Raymond; Gupta, Ramesh Chandra; Jagtap, Vikrant Vijaykumar; Mandhare, Appaji Baburao

Agent Davies Collison Cave

Pub. Number AU-B-2005229416

PCT Pub. Number WO2005/095418

Priority 60/559,184 02.04.04 US

Filing date 1 April 2005

Wipo publication date 13 October 2005

Acceptance publication date 26 March 2009

International Classifications

C07D 513/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or

Event Publications

5 October 2006 PCT application entered the National Phase

  PCT publication WO2005/095418 Priority application(s): WO2005/095418

26 March 2009 Application Accepted

  Published as AU-B-2005229416

23 July 2009 Standard Patent Sealed

25 October 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005229417-Plan nutrient based on o,p-ethylene(bis)hydroxyphenyl glycines

2005229415-Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions